SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Make a comment > Terms and Conditions

  1. When posting or reading you agree:
    1. To accept full responsibility for the views you contribute.
    2. To use this function only for lawful purposes.
    3. Not to post defamatory, abusive, offensive, racist, sexist, threatening, vulgar, obscene, hateful or otherwise inappropriate comments, or to post comments which will constitute a criminal offence or give rise to civil liability.
    4. Not to post or make available any material which is protected by copyright, trade mark or other proprietary right without the express permission of the owner of the copyright, trade mark or any other proprietary right.
    5. Not to post any content that is advertising related.
    6. To evaluate for yourself the accuracy of any opinion, advice or other content.
    7. To supply your name and e mail address.
  2. Complaints
    1. You wish to complain about any content please use the "Report Abuse" feature and include details of your complaint, what action you would like us to take and how we can contact you.
  3. Monitoring
    1. Contributions to Make A Comment will be moderated before being published. If our attention is drawn to allegedly inappropriate content we reserve the right remove the material or the comment.
    2. Comments displaying advertising material will not be published.
    3. We reserve the right not to publish comments. Correspondence with contributors over comments which have been declined for publication will not be entertained.
  4. General
    1. We reserve the right to reveal your identity and contact details to third parties if we believe that you may have breached any of our terms and conditions.
    2. By posting material on Make a Comment, you grant all other users the right to obtain access to this material.
    3. You acknowledge that the author of each contribution is responsible for his or her comments.
    4. We are not responsible for the accuracy, veracity or reliability of any opinion, advice or statement made on Make A Comment unless it is edited by us. If un-modified by us, contributions shall not be considered to be reviewed, edited or approved by William Reed Business Media.
    5. Readers are asked to keep their comments concise and relevant to the topic in question.

Spotlight

Third time's a charm: Pfizer to buy Hospira for $17bn
breaking news

Third time's a charm: Pfizer to buy Hospira for $17bn

Pfizer has entered into a definitive merger agreement to buy Hospira for $17bn.

Vertellus buys antiretroviral API reagent plant from Dow

Vertellus buys antiretroviral API reagent plant from Dow

Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a...

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices...

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a...

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as...